MY117156A - Pharmaceutical composition for oral administration - Google Patents

Pharmaceutical composition for oral administration

Info

Publication number
MY117156A
MY117156A MYPI98005880A MYPI9805880A MY117156A MY 117156 A MY117156 A MY 117156A MY PI98005880 A MYPI98005880 A MY PI98005880A MY PI9805880 A MYPI9805880 A MY PI9805880A MY 117156 A MY117156 A MY 117156A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
oral administration
hydrochloride
trifluoromethylphenyl
cyclodextrin
Prior art date
Application number
MYPI98005880A
Inventor
Claude Aleman
Philippe Bastard
Marielle Bonnel
Thierry Breul
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY117156A publication Critical patent/MY117156A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

THE PRESENT INVENTION RELATES TO AN AQUEOUS SOLUTION CONTAINING 1-[2- (2-NAPHTHYL) ETHYL] -4- (3- TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE (HYDROCHLORIDE OF SR 57746), ALSO COMPRISING ß -CYCLODEXTRIN (ß-CD) AND A PHARMACEUTICALLY ACCEPTABLE ACID OR BUFFER TO GIVE A PH OF LESS THAN OR EQUAL TO 3.
MYPI98005880A 1997-12-24 1998-12-24 Pharmaceutical composition for oral administration MY117156A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (en) 1997-12-24 1997-12-24 AQUEOUS SOLUTION OF 1- [2- (2-NAPHTYL) ETHYL] -4- (3-TRIFLUOROMETHYLPHENYL) CHLORHYDRATE -1,2,3,6-TETRAHYDROPYRIDINE AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING

Publications (1)

Publication Number Publication Date
MY117156A true MY117156A (en) 2004-05-31

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98005880A MY117156A (en) 1997-12-24 1998-12-24 Pharmaceutical composition for oral administration

Country Status (25)

Country Link
US (1) US6191137B1 (en)
EP (1) EP1041984B1 (en)
JP (1) JP2002510599A (en)
AR (1) AR017722A1 (en)
AT (1) ATE252384T1 (en)
AU (1) AU1880599A (en)
BR (1) BR9814414A (en)
CA (1) CA2315696C (en)
CO (1) CO4970813A1 (en)
DE (1) DE69819203T2 (en)
DK (1) DK1041984T3 (en)
DZ (1) DZ2676A1 (en)
ES (1) ES2209238T3 (en)
FR (1) FR2772614B1 (en)
GT (1) GT199800204A (en)
HU (1) HUP0101012A3 (en)
MY (1) MY117156A (en)
NO (1) NO20003284L (en)
PT (1) PT1041984E (en)
SA (2) SA99191002B1 (en)
SI (1) SI1041984T1 (en)
TW (1) TW536409B (en)
UY (1) UY25320A1 (en)
WO (1) WO1999033466A1 (en)
ZA (1) ZA9811824B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (en) * 1993-03-18 1995-06-16 Sanofi Elf USE OF TETRAHYDROPYRIDINE DERIVATIVES FOR THE PREPARATION OF CARDIOPROTECTIVE DRUGS.

Also Published As

Publication number Publication date
AR017722A1 (en) 2001-09-12
CO4970813A1 (en) 2000-11-07
BR9814414A (en) 2000-10-10
SI1041984T1 (en) 2004-04-30
JP2002510599A (en) 2002-04-09
EP1041984B1 (en) 2003-10-22
DZ2676A1 (en) 2004-09-19
DE69819203D1 (en) 2003-11-27
HUP0101012A3 (en) 2002-12-28
EP1041984A1 (en) 2000-10-11
ES2209238T3 (en) 2004-06-16
HUP0101012A2 (en) 2001-08-28
PT1041984E (en) 2004-02-27
DK1041984T3 (en) 2004-02-16
AU1880599A (en) 1999-07-19
WO1999033466A1 (en) 1999-07-08
UY25320A1 (en) 2000-10-31
NO20003284D0 (en) 2000-06-22
NO20003284L (en) 2000-08-24
FR2772614A1 (en) 1999-06-25
ZA9811824B (en) 1999-06-29
CA2315696C (en) 2008-01-29
GT199800204A (en) 2000-06-14
FR2772614B1 (en) 2000-03-10
SA99191003B1 (en) 2006-10-02
TW536409B (en) 2003-06-11
CA2315696A1 (en) 1999-07-08
ATE252384T1 (en) 2003-11-15
DE69819203T2 (en) 2004-07-15
US6191137B1 (en) 2001-02-20
SA99191002B1 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
MX9505064A (en) Orally used pharmaceutical composition,.
MX9505065A (en) Orally used pharmaceutical composition,.
AU2636797A (en) Fast disintegrating oral dosage form
IL123962A (en) 1-(1,2-disubstituted piperidinyl) -4-substituted piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
IL119647A (en) Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it
HUP0201275A3 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
YU8701A (en) New oral formulation
CA2316985A1 (en) Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
UA41978C2 (en) N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl]-2,2-diphenylacetamide hydrochloride, a PROCESS for the preparation thereof and a pharmaceutical composition
BR9811937A (en) Method of increasing the bioavailability of fexofenadine and its derivatives
ATE245028T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TRIMEGESTONE
MX9708394A (en) Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation.
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
MY117156A (en) Pharmaceutical composition for oral administration
DZ3055A1 (en) Polymorphs of crystalline azo-bicyclo-2,2,2-oct-3-ylamine hydrochloride and pharmaceutical compositions containing them.
ATE159254T1 (en) N-((1-(4-FLUOROPHENOXY)BUTYL)-4-PIPERIDINYL)-N-METHYLAMINO-2-BENZOTHIAZOLYL AS CLASS III ANTIARRYTHMICS
NZ332545A (en)
HUP0102895A3 (en) Cyclopentanone dihydropyridine derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.
HUP9800707A3 (en) Phenoxymethyl piperidine derivatives, process for producing them, and pharmaceutical compositions containing them
NZ336129A (en) Micro-particulate form of a tetrahydropyridin derivative (SR 57746)